Open Access

Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway

  • Authors:
    • Zhaoyun Liu
    • Hui Liu
    • Xin Yuan
    • Yihao Wang
    • Lijuan Li
    • Guojin Wang
    • Jia Song
    • Zonghong Shao
    • Rong Fu
  • View Affiliations

  • Published online on: January 26, 2018     https://doi.org/10.3892/ol.2018.7865
  • Pages: 4079-4086
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Pim-2 is a serine/threonine protein kinase that is highly expressed in various types of cancer, with essential roles in the regulation of signal transduction cascades, which promote cell survival and proliferation. The present study demonstrated that Pim‑2 was expressed in cells lines derived from hematopoietic tumors and lung cancer. In vitro, downregulation of Pim‑2 by short interfering RNA inhibited proliferation and delayed G0/G1 cell cycle progression in K562 leukemia, RPMI‑8226 multiple myeloma, and H1299 and A549 non‑small cell lung carcinoma cell lines. Furthermore, downregulation of Pim‑2 resulted in upregulation of cyclin‑dependent kinase (CDK) inhibitor p21, irrespective of the p53 status. In addition, the present study revealed that CDK2 and phosphorylated retinoblastoma (pRb) were significantly downregulated. This finding suggested that inhibition of CDK2 and pRb expression via upregulated p21 was involved in the downregulation of Pim‑2‑induced G0/G1 cell cycle arrest in lung cancer and hematopoietic malignancy cells. These results suggested that Pim‑2 may serve a role in hematopoietic tumors, lung cancer proliferation and cell cycle progression by regulating the p21 signaling pathway. Downregulation of Pim‑2 decreased cancer cell proliferation. Therefore, Pim‑2 may be a potential therapy target in clinical cancer therapy.

References

1 

Breuer ML, Cuypers HT and Berns A: Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 8:743–748. 1989.PubMed/NCBI

2 

Yoshida S, Kaneita Y, Aoki Y, Seto M, Mori S and Moriyama M: Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5′-RACE and LA-PCR analyses of biopsy samples. Oncogene. 18:7994–7999. 1999. View Article : Google Scholar : PubMed/NCBI

3 

Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D and Telerman A: The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA. 86:pp. 8857–8861. 1989; View Article : Google Scholar : PubMed/NCBI

4 

Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, et al: The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 25:1182–1188. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D and Ayala G: Pim-2 upregulation: Biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 65:276–286. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Gong J, Wang J, Ren K, Liu C, Li B and Shi Y: Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell. J Surg Res. 153:17–22. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Wang Z, Zhang Y, Gu JJ, Davitt C, Reeves R and Magnuson NS: Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells. Int J Biochem Cell Biol. 42:1030–1038. 2010. View Article : Google Scholar : PubMed/NCBI

8 

van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J and Berns A: Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J. 14:2536–2544. 1995.PubMed/NCBI

9 

Morishita D, Katayama R, Sekimizu K, Tsuruo T and Fujita N: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Losman J, Chen XP, Jiang H, Pan PY, Kashiwada M, Giallourakis C, Cowan S, Foltenyi K and Rothman P: IL-4 signaling is regulated through the recruitment of phosphatases, kinases, and SOCS proteins to the receptor complex. Cold Spring Harb Symp Quant Biol. 64:405–416. 1999. View Article : Google Scholar : PubMed/NCBI

11 

Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, Halperin M, Shalom S, Merkel D and Don J: Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 45:951–955. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Gomez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, González-Menchén A, Martinez-Climent JA, Mata E, Rodríguez ME, Muñoz-González G, Sánchez-Beato M, et al: PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 118:5517–5527. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL and Holash J: Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 122:1610–1620. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, et al: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 6:387–400. 1995. View Article : Google Scholar : PubMed/NCBI

15 

Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 98:859–869. 1999. View Article : Google Scholar : PubMed/NCBI

16 

Mlynarczyk C and Fåhraeus R: Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21(CDKN1A). Nat Commun. 5:50672014. View Article : Google Scholar : PubMed/NCBI

17 

Gartel AL and Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 246:280–289. 1999. View Article : Google Scholar : PubMed/NCBI

18 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

19 

Gartel AL, Serfas MS and Tyner AL: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med. 213:pp. 138–149. 1996; View Article : Google Scholar : PubMed/NCBI

20 

Weinberg RA: The retinoblastoma protein and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI

21 

Bertoli C, Skotheim JM and de Bruin RA: Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Lowe SW and Lin AW: Apoptosis in cancer. Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest. 115:2618–2624. 2005. View Article : Google Scholar : PubMed/NCBI

24 

Jiang JX, Mikami K, Venugopal S, Li Y and Török NJ: Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol. 51:139–148. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Loewer A, Batchelor E, Gaglia G and Lahav G: Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell. 142:89–100. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Hogan C, Hutchison C, Marcar L, Milne D, Saville M, Goodlad J, Kernohan N and Meek D: Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem. 283:18012–18023. 2008. View Article : Google Scholar : PubMed/NCBI

28 

Ren K, Zhang W, Shi Y and Gong J: Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway. Pathol Oncol Res. 16:229–237. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T and Thompson CB: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res. 64:8341–8348. 2004. View Article : Google Scholar : PubMed/NCBI

30 

White E: The pims and outs of survival signaling: Role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 17:1813–1816. 2003. View Article : Google Scholar : PubMed/NCBI

31 

Xia Y, Shen S and Verma IM: NF-κB, an active player in human cancers. Cancer Immunol Res. 2:823–830. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA and Thompson CB: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17:1841–1854. 2003. View Article : Google Scholar : PubMed/NCBI

33 

Ghosh S, Tergaonkar V, Rothlin CV, Correa RG, Bottero V, Bist P, Verma IM and Hunter T: Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell. 10:215–226. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Z., Liu, H., Yuan, X., Wang, Y., Li, L., Wang, G. ... Fu, R. (2018). Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway. Oncology Letters, 15, 4079-4086. https://doi.org/10.3892/ol.2018.7865
MLA
Liu, Z., Liu, H., Yuan, X., Wang, Y., Li, L., Wang, G., Song, J., Shao, Z., Fu, R."Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway". Oncology Letters 15.4 (2018): 4079-4086.
Chicago
Liu, Z., Liu, H., Yuan, X., Wang, Y., Li, L., Wang, G., Song, J., Shao, Z., Fu, R."Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway". Oncology Letters 15, no. 4 (2018): 4079-4086. https://doi.org/10.3892/ol.2018.7865